Calcitonin Gene-Related Peptide Inhibitors in the Treatment of Migraine in the Pediatric and Adolescent Populations: A Review

被引：3
作者：
Moore, Lisa [1 ,2 ]
Pakalnis, Ann [1 ,2 ]
机构：
[1] Nationwide Childrens Hosp, Dept Neurol, Columbus, OH USA
[2] Ohio State Univ, Wexner Med Ctr, Dept Neurol, 395 W 12th Ave,7th Floor, Columbus, OH 43210 USA
来源：
PEDIATRIC NEUROLOGY | 2024年 / 157卷
关键词：
Migraine; Headache; Pediatric; Adolescent; Calcitonin gene-related peptide; Calcitonin gene-related peptide inhibitors; CGRP; CGRP inhibitors; CGRP MONOCLONAL-ANTIBODIES; PREVENTIVE TREATMENT; SPREADING DEPRESSION; ELECTRICAL-STIMULATION; DOUBLE-BLIND; OPEN-LABEL; HEADACHE; PLACEBO; AURA; PREVALENCE;
D O I：
10.1016/j.pediatrneurol.2024.05.013
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
There are limited well-studied treatments for migraine in the pediatric population. Calcitonin gene- related peptide (CGRP) inhibitors are an established safe and effective treatment in adults, and use may be appropriate for pediatric patients in certain clinical situations. We describe migraine pathophysiology as it relates to CGRP, provide an overview of available medications, and discuss clinical usage in this population. Published by Elsevier Inc.
引用
收藏
页码：87 / 95
页数：9
相关论文
共 125 条
[1]   Atogepant for the Preventive Treatment of Migraine [J].
Ailani, Jessica ;
Lipton, Richard B. ;
Goadsby, Peter J. ;
Guo, Hua ;
Miceli, Rosa ;
Severt, Lawrence ;
Finnegan, Michelle ;
Trugman, Joel M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08) :695-706
[2]  
AJOVY (Fremanezumab-vfrm), 2019, injection prescribing information
[3]   Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study [J].
Alsaadi, Taoufik ;
Suliman, Reem ;
Santos, Vanessa ;
Al Qaisi, Ibrahim ;
Carmina, Princess ;
Aldaher, Batool ;
Haddad, Shadi ;
Bader, Yazan .
NEUROLOGY AND THERAPY, 2024, 13 (02) :465-473
[4]   Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis [J].
Andreou, Anna P. ;
Fuccaro, Matteo ;
Hill, Bethany ;
Murphy, Madeleine ;
Caponnetto, Valeria ;
Kilner, Rachael ;
Lambru, Giorgio .
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01)
[5]  
[Anonymous], 2023, Qulipta (Atogepant) oral tablets prescribing information
[6]  
[Anonymous], 2021, Aimovig (Erenumab-aooe) injection prescribing information
[7]  
[Anonymous], 2021, EMGALITY GALCANEZUMA
[8]  
[Anonymous], 2018, FDA approves novel preventive treatment for migraine
[9]  
[Anonymous], 2019, FDA approves Emgality (galcanezumab-gnlm) as the first and only medication for the treatment of episodic cluster headache that reduces the frequency of attacks
[10]  
[Anonymous], 2023, U.S. FDA approves QULIPTA (atogepant) for adults with chronic migraine
12345678910